TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Is Upregulated in Lymphocytes Stimulated with Concanavalin A.
Apoptosis
Apoptosis Regulatory Proteins
/ genetics
Autophagy
Concanavalin A
/ pharmacology
Gene Expression Regulation
/ drug effects
Glycolysis
Humans
Lymphocytes
/ drug effects
Mitogens
/ pharmacology
Pentose Phosphate Pathway
Phosphatidylinositol 3-Kinases
/ chemistry
Phosphoric Monoester Hydrolases
/ genetics
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Signal Transduction
PI3K/AKT
PPP
ROS
TIGAR
autophagy
glycolysis
lymphocytes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Jul 2021
11 Jul 2021
Historique:
received:
28
05
2021
revised:
06
07
2021
accepted:
07
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
30
7
2021
Statut:
epublish
Résumé
The glycolytic modulator TP53-Inducible Glycolysis and Apoptosis Regulator (TIGAR) is overexpressed in several types of cancer and has a role in metabolic rewiring during tumor development. However, little is known about the role of this enzyme in proliferative tissues under physiological conditions. In the current work, we analysed the role of TIGAR in primary human lymphocytes stimulated with the mitotic agent Concanavalin A (ConA). We found that
Identifiants
pubmed: 34299056
pii: ijms22147436
doi: 10.3390/ijms22147436
pmc: PMC8303789
pii:
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
Mitogens
0
Concanavalin A
11028-71-0
AKT1 protein, human
EC 2.7.11.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Phosphoric Monoester Hydrolases
EC 3.1.3.2
TIGAR protein, human
EC 3.1.3.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00412
Organisme : Gestió d'Ajuts Universitaris i de Recerca de la Generalitat de Catalunya
ID : FI-DGR 2015
Organisme : Astellas European Foundation
ID : Award (13th European Society of Transplantation)
Organisme : ISCIII Miguel Servet
ID : CP06/00067
Organisme : REDinREN
ID : RD12/0021/003
Références
Leukemia. 2009 Nov;23(11):2090-101
pubmed: 19710698
Cell Signal. 2017 Jun;34:23-37
pubmed: 28235572
Mol Immunol. 2015 Dec;68(2 Pt C):497-506
pubmed: 26277275
Curr Opin Immunol. 2016 Apr;39:v-vii
pubmed: 26923180
Oncol Lett. 2019 Sep;18(3):2509-2517
pubmed: 31402948
J Biol Chem. 2016 Dec 16;291(51):26291-26303
pubmed: 27803158
Cancer Res. 2014 Sep 15;74(18):5127-38
pubmed: 25085248
Oncol Rep. 2016 Mar;35(3):1281-6
pubmed: 26675982
Cell Mol Neurobiol. 2015 Jul;35(5):615-21
pubmed: 25722131
J Transl Med. 2012 May 16;10:95
pubmed: 22591674
FEBS Lett. 2016 Sep;590(17):2915-26
pubmed: 27491040
Mol Cell Biochem. 2018 Nov;448(1-2):187-197
pubmed: 29435871
Nat Rev Immunol. 2020 Jan;20(1):55-70
pubmed: 31406325
Osteoarthritis Cartilage. 2018 Jan;26(1):138-148
pubmed: 29061494
Biochimie. 2015 Nov;118:26-35
pubmed: 26212201
Curr Opin Immunol. 2014 Apr;27:60-74
pubmed: 24556090
Front Oncol. 2018 Sep 04;8:331
pubmed: 30234009
Cancer Metab. 2014 Jan 03;2(1):1
pubmed: 24383451
Biomol Ther (Seoul). 2018 Jan 1;26(1):29-38
pubmed: 29212304
Int J Mol Sci. 2019 Mar 01;20(5):
pubmed: 30823646
Sci Rep. 2015 Apr 30;5:9853
pubmed: 25928429
Dev Cell. 2013 Jun 10;25(5):463-77
pubmed: 23726973
Immunity. 2002 Jun;16(6):769-77
pubmed: 12121659
Immunity. 2013 Feb 21;38(2):201-2
pubmed: 23438817
J Exp Med. 2015 Aug 24;212(9):1345-60
pubmed: 26261266
Br J Pharmacol. 2019 Apr;176(7):919-937
pubmed: 30710454
Radiother Oncol. 2011 Oct;101(1):132-9
pubmed: 21864926
Nat Rev Immunol. 2002 Apr;2(4):251-62
pubmed: 12001996
EMBO J. 2009 Oct 7;28(19):3015-26
pubmed: 19713938
Cell. 2006 Jul 14;126(1):107-20
pubmed: 16839880
Cancer Cell. 2020 Feb 10;37(2):168-182.e4
pubmed: 31983610
Immunity. 2011 Dec 23;35(6):871-82
pubmed: 22195744
Virology. 2018 Jul;520:39-58
pubmed: 29777913
Biochemistry. 1967 Jan;6(1):105-11
pubmed: 6030308
Cancer Lett. 2017 Dec 28;411:12-18
pubmed: 28974448